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Abstract
Background: Identification of modifier genes and characterization of their effects represent major challenges in human
genetics. SAA1 is one of the few modifiers identified in humans: this gene influences the risk of renal amyloidosis (RA) in
patients with familial Mediterranean fever (FMF), a Mendelian autoinflammatory disorder associated with mutations in
MEFV. Indeed, the SAA1 a homozygous genotype and the p.Met694Val homozygous genotype at the MEFV locus are two
main risk factors for RA.
Methodology/Principal Findings: Here, we investigated Armenian FMF patients and controls from two neighboring
countries: Armenia, where RA is frequent (24%), and Karabakh, where RA is rare (2.5%). Sequencing of MEFV revealed similar
frequencies of p.Met694Val homozygotes in the two groups of patients. However, a major deficit of SAA1 a homozygotes
was found among Karabakhian patients (4%) as compared to Armenian patients (24%) (p=5.10
25). Most importantly, we
observed deviations from Hardy-Weinberg equilibrium (HWE) in the two groups of patients, and unexpectedly, in opposite
directions, whereas, in the two control populations, genotype distributions at this locus were similar and complied with
(HWE).
Conclusions/Significance: The excess of SAA1a homozygotes among Armenian patients could be explained by the
recruitment of patients with severe phenotypes. In contrast, a population-based study revealed that the deficit of a/a
among Karabakhian patients would result from a negative selection against carriers of this genotype. This study, which
provides new insights into the role of SAA1 in the pathophysiology of FMF, represents the first example of deviations from
HWE and selection involving the modifier gene of a Mendelian disorder.
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Introduction
Interest in modifier genes keeps growing because of their ability
to modulate the expression of monogenic or multigenic traits and
diseases [1,2]. SAA1, which encodes the serum amyloid A protein,
is one of the few modifier genes identified in humans [3]. Three
SAA1 allelic variants have been defined on the basis of two single
nucleotide polymorphisms located in exon 3 (c.209C.T–p.Ala52-
Val and c.224T.C–p.Val57Ala): a (c.209T, c.224C), b (c.209C,
c.224T) and c (c.209C, c.224C). We previously demonstrated that
the SAA1 a/a genotype is associated with an increased risk to
develop renal amyloidosis (RA) in Armenian patients suffering
from familial Mediterranean fever (FMF [MIM 249100]) [3], a
result that was secondarily confirmed in other populations of FMF
patients [4–7]. FMF, which belongs to the expanding family of
autoinflammatory disorders, is an autosomal recessive disorder
associated with mutations in the MEFV gene [8,9]. The effect of
the SAA1 a/a genotype on the severity of the disease phenotype,
therefore, reveals an epistatic interaction between SAA1 and
MEFV. FMF is characterized by recurrent episodes of fever and
systemic inflammation, usually revealed by sterile peritonitis,
arthritis and/or pleurisy. During attacks, patients have elevated
levels of acute phase reactants, especially of SAA, that leads in
some patients to RA as a result of renal deposition of protein
amyloid A. This reactive systemic amyloidosis, called AA-
amyloidosis, which may develop over years and progress to
terminal renal failure, is the major complication of FMF [10].
FMF primarily affects people originating from the Mediterra-
nean basin, especially Armenian, Sephardic Jewish, Turkish and
Arab populations. The prevalence of FMF in Armenia and in
Karabakh, a region close to Armenia inhabited by Armenian
people, is particularly high ranging from 0.5 to 1.5% [11]. Several
studies, performed before the introduction of colchicine treatment,
reported different prevalences of RA in Armenian FMF patients
living in different countries: 24% in Armenia [12], 7.5% in
Lebanon [13] and 0% in California [14]. However, to date there
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been noted that RA is rare among untreated Karabakhian patients
(2.5%, Sarkisian, unpublished observations), as compared to
untreated patients living in Armenia (24%, [12], Sarkisian,
unpublished data), therefore suggesting the presence of a
protective factor in Karabakh.
Results and Discussion
Difference in SAA1 genotype distributions between
Armenian and Karabakhian patients
The difference in the prevalence of FMF-associated renal
amyloidosis in patients from Armenia and from Karabakh
prompted us to compare, in these two populations, the genetic
factors known to influence the risk to develop RA: the
p.Met694Val homozygous genotype at the MEFV locus (disease-
causing gene) and the a homozygous genotype at the SAA1 locus
(modifier gene), each of these two factors being associated with a
sevenfold increased risk for RA [3]. Sequencing of MEFV did not
reveal any significant difference in the frequency of p.Met694Val
homozygotes between Armenian and Karabakhian patients
(Table 1). However, sequencing of SAA1 revealed that the
frequency of FMF patients with the a/a genotype was much
higher in Armenia (f=0.24) than in Karabakh (f=0.04)
(p=5.10
25, 1d.f.) (Table 2). At first glance, these data suggest
that the low frequency of the a/a genotype among patients from
Karabakh could account for the low prevalence of amyloidosis in
that region. These observations led us to investigate in more details
the role of the SAA1 modifier in patients from Armenia and from
Karabakh, as well as in matched population controls.
Opposite deviations from HWE of SAA1 genotype
distributions among Armenian and Karabakhian patients
We first investigated the genotype and allele distributions at the
SAA1 locus in Armenian and Karabakhian control groups (Fig. 1A
and 1B). We observed that the most frequent SAA1 alleles
correspond to a and b variants (frequency in Armenia of 0.32 and
0.66, respectively; frequency in Karabakh of 0.35 and 0.63,
respectively), whereas the c allele is very rare (frequency in
Armenia and Karabakh of 0.02). Since a is the SAA1 allele
involved in the risk to develop RA in Armenian FMF patients, b
and c alleles were merged into a single allele category termed ‘‘o’’
(standing for other alleles) in subsequent statistical analyses. Then,
we compared the distribution of SAA1 genotypes in controls from
Karabakh and Armenia (Fig. 1A) by means of a chi-square test of
homogeneity. No difference was observed (p=0.53, 2d.f., Fig. 2), a
result allowing to consider the Karabakhian and Armenian
controls as a single homogeneous control group. In addition, as
shown by chi-square tests, these distributions at the SAA1 locus fit
with Hardy-Weinberg equilibrium (HWE) in the two control
groups (Karabakh: p=0.53, Armenia: p=0.41, 1 d.f.) (Fig. 2).
However, a similar analysis performed in the population of
FMF patients living in Armenia revealed that the distribution of
SAA1 genotypes does not comply with HWE (p=1.10
24, 2d.f.,
Fig. 2), and that the frequency of the a/a genotype is much higher
in patients (f=0.24) than in controls (f=0.11) (Fig. 1A)
(p=4.10
23, 1d.f.). The study of the distribution of SAA1 genotypes
among Karabakhian patients also showed a departure from HWE
(p-value for the chi-square test p=0.03, 2d.f., Fig. 2), but,
unexpectedly, with a lower frequency of a homozygotes in patients
(f=0.04) than in controls (f=0.1) (Fig. 1A, p=0.04, 1d.f.).
Consequently, the frequency of a homozygotes differs dramatically
between Karabakhian (f=0.04) and Armenian patients (f=0.24)
(Fig. 1A, p=5.10
25, 1d.f.). To further confirm these data, we
compared the distributions of SAA1 genotypes observed in
Armenian and Karabakhian patients to the fluctuations expected
in samples under the assumption of HWE, using a Monte Carlo
algorithm. Indeed, for large samples (n.30), Monte Carlo
simulations, which are easy statistical tools to represent variations
due to stochastic fluctuations, are more appropriate than chi-
square tests to determine whether a given population follows the
Hardy-Weinberg law [15,16]. Based on the frequency of the
different SAA1 alleles calculated in the Armenian and Karaba-
khian groups of patients, we performed 10
6 random simulations of
the SAA1 genotype distributions expected under HWE in samples
of 100 and 99 individuals, respectively. We represented the
probability of each genotype distribution on a three-dimensional
(3D)-graph displaying the number of a homozygotes (x-axis) as a
function of the number of a heterozygotes (a/o) (y-axis) and the
number of occurrences for each genotype distribution (z-axis)
(Fig. 3). Since we used a high number of simulations, sampling
variations are represented as a 3D-Gaussian curve. As shown in
Fig. 3A and 3B, the SAA1 genotype distributions observed in the
Karabakhian and Armenian groups of patients correspond to very
rare events (dots located at far extremities of the 3D curves). This
second independent statistical approach therefore confirmed
major and opposite departures from HWE in the group of FMF
Armenian patients (p,5.10
25) that showed a large excess of a
homozygotes, and in the group of Karabakhian patients
(p,5.10
24) that displayed a major lack of a homozygotes.
At this point, it is important to underline the fact that correct
interpretation of HWE deviations depends on the reliability of
genotyping. In this regard, and as detailed in the Materials and
Methods section, we followed a number of experimental
safeguards to ensure its accuracy. In addition, the fact that
HWE deviations were absent in control groups and found in
opposite directions in the Armenian and Karabakhian populations
of patients also strongly argues against genotyping errors, all the
more since all samples (from Armenian and Karabakhian
individuals) were processed at the same time and following
identical experimental procedures.
Table 1. Comparison of the MEFV p.Met694Val homozygous
genotype frequencies in Armenian and Karabakhian FMF
patients.
MEFV genotype
Armenian
patients No. (%)
Karabakhian
patients No. (%) p-value
p.Met694Val/
p.Met694Val
23 (0.23) 30 (0.3)
other 77 (0.77) 69 (0.7)
0.24
doi:10.1371/journal.pone.0007676.t001
Table 2. Comparison of the SAA1 a homozygous genotype
frequencies in Armenian and Karabakhian FMF patients.
SAA1 genotype
Armenian
patients No. (%)
Karabakhian
patients No. (%) p-value
a/a 24 (0.24) 4 (0.04)
other 76 (0.76) 95 (0.96)
5.10
25
doi:10.1371/journal.pone.0007676.t002
SAA1 and Negative Selection
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How the deviation from HWE observed in Armenian patients
could be explained? Family history of each patient revealed no
consanguinity that could account for such a deviation. Genetic
drift can also be excluded since the distributions of SAA1 genotypes
complied with HWE in the Armenian control group. Therefore,
the most likely explanation for this increase in SAA1 a
homozygotes among patients is the recruitment of severe forms
of the disease, thereby underlining the prognostic value of the
SAA1 a/a genotype [3–7]. As for the deviation from HWE
observed in the Karabakhian population of patients, it was, in that
case, associated with a deficit of SAA1 a/a. Consanguinity was also
ruled out on family history; in addition, consanguinity would have
led to an increase of homozygotes, a situation opposite to the one
observed. A selection bias can be excluded because it would have
favored the recruitment of patients with severe phenotypes and, as
discussed above, it would have increased the frequency of a
homozygotes. Genetic drift can also lead to HWE departures in
populations of limited size due to random fluctuations of allelic
frequencies from one generation to the next one [17]. However,
the fact that the HWE disequilibrium observed in Karabakh was
found only in the subset of FMF patients and not in controls
discards this hypothesis. Mixed populations is another common
cause of deviation from HWE since population substructure leads
to a reduction of heterozygotes, a phenomenon called the
Wahlund effect [18]; however, in the present study, the proportion
of a heterozygotes is not reduced but even higher than expected,
thereby strongly arguing against population substructure. The only
reasonable interpretation for the observed departure from HWE is
therefore selection against FMF patients carrying the a homozy-
gous genotype. This conclusion is also supported by the fact that
this particular SAA1 genotype has been shown to be a major
severity factor of the disease in all populations investigated so far
[3–7]. The negative selection would occur very early, possibly
leading to abortion, since no case of early death has been observed
among Karabakhian patients with FMF. Given the prevalence of
FMF in Karabakh (,0.01) and the frequency of the alpha/alpha
genotype in this area (,0.1), the expected percentage of
Figure 1. SAA1 genotype and allele distributions in Armenian and Karabakhian FMF patients and controls. A. Genotype frequencies. B.
Allele frequencies. Ar=Armenia, K=Karabakh. o stands for ‘‘other allele’’ that includes b and c alleles; since the frequency of the c allele is very low in
Armenian individuals, b and c alleles were pooled for statistical analyses. Numbers in brackets correspond to the numbers of individuals in each
category.
doi:10.1371/journal.pone.0007676.g001
Figure 2. Comparison of SAA1 genotype distributions to theoretical proportions expected from HWE. Ob=observed, HW=expected
under HWE, Ar=Armenia, K=Karabakh. In the two groups of patients, the genotype distributions expected under HWE were calculated using the
allele frequencies of the control group; in that case, we used a chi-square test with 2 degrees of freedom.
doi:10.1371/journal.pone.0007676.g002
SAA1 and Negative Selection
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1.10
23); a negative selection could, therefore, easily pass
unnoticed. The study of the Karabakhian history reveals that
Karabakhian and Armenian populations have evolved relatively
independently since several centuries [19]; consequently, and as an
example, it has been demonstrated that the spectrum of MEFV
mutations (nature and frequency) differs in the two populations,
although the frequency of the particular p.Met694Val homozy-
gous genotype, the one that increases the risk of renal amyloidosis,
is similar among Karabakhian and Armenian patients [20,21]. In
this context, we wondered whether a particular SAA1 allelic
variant could be present in Karabakh. Sequencing of the entire
SAA1 gene revealed 53 polymorphisms (including the 2 polymor-
phisms defining the a, b and c alleles), but none of them was found
more frequently in Karabakhian than in Armenian individuals
(data not shown). It is therefore likely that the lack of SAA1 a
homozygotes in Karabakh brings into play other as-yet-unknown
genes and/or environmental factors.
Identification of modifier genes and characterization of their
associated effects represent one of the main and most difficult
current challenges in human genetics. In the present study, we
identified a new characteristic of the SAA1 modifier. We observed
a major difference in the distribution of SAA1 genotypes in two
groups of patients from the same origin but living in neighboring
countries, though no difference was observed in matched control
groups. Furthermore, we observed significant deviations from
HWE in the two groups of patients, but strikingly in opposite
directions. Our data strongly suggest that SAA1 not only
influences the severity of FMF, but is also involved in a negative
selection process against Karabakhian FMF patients carrying the
SAA1 a/a genotype. Very few studies have reported the
involvement of disease-causing or susceptibility genes in negative
selection processes in humans [22–25]. To the best of our
knowledge, this is the first study showing deviations from HWE
and selection involving a modifier gene involved in a Mendelian
disorder.
Materials and Methods
Subjects
The study was approved by the Institutional Review Board of
the Ministry of Health (Republic of Armenia). We investigated
consecutive unrelated patients originating from Armenia (n=100)
and from Karabakh (n=99) who came to hospital and in whom
the diagnosis of FMF was made according to established clinical
criteria [26]. Clinical features were recorded through a standard-
ized form and informed written consent was given by all
individuals. 128 healthy individuals from Armenia and 62 from
Karabakh were investigated as controls. All individuals are of
Armenian descent. Each study group consists of individuals that
are not related to the first, second or third degree.
Screening of the MEFV and SAA1 genes
Mutations in MEFV were screened as described previously [3].
The SAA1 gene was amplified by PCR (Expand Long Template
PCR System, Roche) from genomic DNA using forward (59-
tgacctgcagggactttccccagg-39) and reverse (59-aactcatcatgtccttgcct-
cagg-39) primers. PCR products, run on agarose gels together with
a negative control to detect any possible contamination, were then
purified using the Wizard PCR Clean-Up System (Promega),
sequenced with both forward and reverse primers using the ABI
PRISM Big Dye Terminator V3.1 ready reaction cycle sequencing
kit, and processed on a Genetic Analyzer ABI 3100 (Applied
Biosystems). Electrophoregrams, analyzed by a dedicated software,
were also read independently by two persons. Samples from
Armenian and from Karabakhian individuals were processed at
the same time using identical experimental conditions.
Statistical analyses
Pearson’s chi-square tests were used to compare the frequencies
of p.Met694Val homozygotes and SAA1 a/a homozygotes in the
different groups. The compliance with HWE of SAA1 genotype
distributions was also tested using chi-square tests. In the 2 groups
Figure 3. Comparison of SAA1 genotype distributions to sampling fluctuations in populations under the assumption of HWE. A.
Comparison in Armenian patients. A Monte Carlo algorithm was used to represent the data from 10
6 simulations of SAA1 genotype distributions in
samples of 100 individuals assuming that the a allele frequency is 0.32 (i.e. frequency in the Armenian control group). The 3D representation shows
the number of occurrences for each genotype distribution (z-axis) according to the number of a homozygotes and a heterozygotes (x- and y-axis,
respectively) in a Cartesian coordinate system. The position of the genotype distribution observed in Armenian patients is plotted as a red dot
(position 24;41). B. Comparison in Karabakhian patients. Same as in A with the representation of the data from 10
6 simulations in samples of 99
individuals, assuming that the a allele frequency is 0.35 (i.e. frequency in the Karabakhian control group). The position of genotype distribution
observed in Karabakhian patients is plotted as a yellow dot (position 4;54).
doi:10.1371/journal.pone.0007676.g003
SAA1 and Negative Selection
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calculated using the allele frequencies of the control group
including Armenian and Karabakhian controls; compliance with
HWE was assessed using chi-square tests with 2 degrees of
freedom. We used a Monte Carlo algorithm to represent in a 3D
model the expected variations of SAA1 genotype distributions due
to stochastic sampling fluctuations in populations under the
assumption of HWE: iterative (n=10
6) sample simulations of
sizes matching those of the two groups of patients (n=100 for
Armenia and n=99 for Karabakh) were performed using the
SAA1 allele frequencies estimated in the corresponding control
groups (f(a)=0.32 and 0.35 in Armenia and Karabakh, respec-
tively). The number of occurrences for each genotype distribution
is represented in a Cartesian coordinate system, the juxtaposition
of all simulations leading to a 3D Gaussian curve.
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